Summary & Overview
HCPCS J0739: Cabotegravir Injection for HIV Pre-Exposure Prophylaxis
HCPCS Level II code J0739 denotes a 1 mg injection of cabotegravir approved for HIV pre-exposure prophylaxis (PrEP) and explicitly not for HIV treatment. The code identifies the drug product and its use in preventive HIV care, an increasingly important component of national public health strategies to reduce HIV transmission. As long-acting injectable PrEP options expand, accurate coding for drug administration and coverage determinations affect access and reporting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national perspective on coverage practices and billing considerations for cabotegravir PrEP across major commercial and federal payers. Readers will find benchmarks for payer coverage and prior authorization trends, summaries of relevant policy updates affecting outpatient injectable PrEP, and clinical context for where and how J0739 is used in care delivery.
This summary equips billing managers, coding specialists, and policy analysts with a concise reference to the code's clinical purpose, typical service settings, and the payer landscape. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J0739 describes an injection of cabotegravir, 1 mg, specifically noted as an FDA-approved prescription for HIV pre-exposure prophylaxis (PrEP) and not for use as treatment for HIV. The service reflects administration of an antiretroviral agent intended to reduce the risk of HIV acquisition in eligible patients.
Service type: Medication administration (injectable antiretroviral for PrEP)
Typical site of service: Outpatient clinics, community health centers, sexual health clinics, and other ambulatory care settings where injectable PrEP is administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an HIV-negative adult at substantial ongoing risk for HIV acquisition who presents to an outpatient infectious disease or sexual health clinic for long-acting pre-exposure prophylaxis (PrEP) using cabotegravir. The patient undergoes baseline evaluation including HIV antigen/antibody testing, renal and hepatic function tests, hepatitis B surface antigen, and pregnancy test if applicable. After clinical eligibility is confirmed, the provider administers an intramuscular injection of cabotegravir (J0739 billed per 1 mg unit) in the clinic’s injection suite or an ambulatory procedure room. Follow-up visits are scheduled every 2 months for repeat injections, HIV testing, and safety monitoring. Typical documentation includes indication (HIV PrEP), informed consent, lot number and vial/unit count for J0739, injection site, route (intramuscular), and any immediate adverse reaction. The typical site of service is an outpatient clinic, federally qualified health center, or community health center with clinical staff able to perform intramuscular injections and monitor patients post-injection.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Reserved/Not used for professional/technical reporting | Use only per payer guidance if required; generally not appended for this drug code |